11,332 Results

Interim results from EMPRISE phase III trial of Jardiance show reduced risk of heart failure in Type 2 diabetes with CV disease.- Boehringer + Eli Lilly

 Added 20 hours ago

A new interim analysis of three-year data from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world study on effectiveness shows...

Novartis PARAGON-HF analyses suggest Entresto benefit beyond HFrEF .

 Added 20 hours ago

Novartis announced new subgroup analyses from its global Phase III PARAGON-HF study of patients with heart failure with preserved ejection...

Analysis of phase III TWILIGHT trial for Brilinta showed reduced risk of bleeding in acute coronary syndromes.- AstraZeneca

 Added 20 hours ago

New results from a pre-specified subgroup analysis of the TWILIGHT trial showed that Brilinta (ticagrelor) monotherapy, from AstraZeneca, reduced the...

FDA extends PDUFA date for Twirla, a combined hormonal contraceptive patch, to 16 February 2020.- Agile Therapeutics

 Added 20 hours ago

Agile Therapeutics, Inc. has announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) goal date for...

PROTECTOR 1 Phase III study, evaluating RTB 101 for symptomatic respiratory illness did not meet its primary endpoint.- resTORbio, Inc.

 Added 20 hours ago

resTORbio, Inc.announced that top line data from the PROTECTOR 1 Phase III study, evaluating the safety and efficacy of RTB...

FOURIER outcomes phase III study of Repatha shows effectiveness in myocardial infarction.- Amgen

 Added 1 day ago

Amgen announced a new analysis from the Repatha (evolocumab) cardiovascular outcomes (FOURIER) phase III study that evaluates the effectiveness of...

Advisory Committee recommends Vascepa to reduce the risk of cardiovascular events.- Amarin Corpn.

 Added 1 day ago

Amarin Corporation plc announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the FDA has voted unanimously (16-0)...

CHMP positive for solriamfetol to improve wakefulness and reduce excessive daytime sleepiness in adults with narcolepsy (with or without cataplexy) or obstructive sleep apnea .- Jazz Pharma

 Added 1 day ago

Jazz Pharmaceuticals plc announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a...

Roche to acquire Promedior and with it PRM 151 a proposed treatmemt for fibrotic diseases

 Added 2 days ago

Promedior, Inc.,announced that it has entered into a definitive merger agreement for Roche to acquire Promedior. With this acquisition, Roche...

CHMP recommends approval of Polivy + bendamustine + MabThera for diffuse large B-cell lymphoma.- Roche

 Added 2 days ago

Roche announced that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Polivy...

Load more